Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines

BACKGROUND: The refractory nature of many cancers remains the main health challenge over the past century. The epigenetic drug, decitabine (DAC), represents one of the most promising therapeutic agents in cancers particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chunchao, Suo, Jinfeng, Katayama, Hiroyuki, Wei, Yue, Garcia-Manero, Guillermo, Hanash, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932764/
https://www.ncbi.nlm.nih.gov/pubmed/27382363
http://dx.doi.org/10.1186/s12014-016-9115-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932764/
https://www.ncbi.nlm.nih.gov/pubmed/27382363
http://dx.doi.org/10.1186/s12014-016-9115-z

Ejemplares similares